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ABSTRACT The Met receptor is widely expressed in embryonic and adult epithelial tissues; its ligand
(hepatocyte growth factor/scatter factor, HGF/SF) is expressed in the mesenchymal component of
various organs. The generation of hgf and met null mice has revealed an essential role for this ligand-
receptor pair in the development of the placenta, liver, and limb muscles. However the early lethality
of the null mutants has precluded analysis of Met function in late development. To extend the possible
observation period, we generated mutant met alleles of different severity. This was done by impairing
the ability of the receptor to transduce the HGF/SF signal, via mutation of consensus sequences in the
multifunctional docking site present in the C-terminal tail of the receptor. Mice expressing a Met
mutant still active as a kinase, but unable to recruit its effectors, died in mid-gestation with the same
phenotype as the met knockout, proving the importance of phosphotyrosine-SH2 interactions in vivo.
Mice expressing a Met receptor with partial loss of signaling function survived until birth and revealed
novel aspects of HGF/SF-Met function during muscle development.
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Introduction
Met tyrosine kinase is the receptor for HGF/SF (Bottaro et al.,
1991; Naldini et al., 1991), a mesenchyme-derived pleiotropic
growth factor, active on a variety of target cells. Among these are
hepatocytes, melanocytes, keratinocytes, cells of the mammary,
renal, gastric and biliary epithelium, as well as hematopoietic
precursors, vascular endothelial cells, and neurons. The biological
responses of cultured cells to HGF/SF range from survival and
proliferation, to dissociation of epithelial sheets (scatter) and
branching morphogenesis (for reviews see Gherardi and Stoker,
1991; Zarnegar and Michalopoulos, 1995; Boros and Miller, 1995;
Matsumoto and Nakamura, 1996).
In vivo HGF/SF is a potent angiogenic factor (Bussolino et al.,
1992; Grant et al., 1993) and is involved in regeneration of organs
including liver, kidney and lung (Michalopoulos and De Frances,
1997; Matsumoto and Nakamura, 1997; Balkovetz and Lipschutz,
1999). Altered met expression and constitutive activation of the
receptor have been described in human tumours and cell lines,
suggesting a role for Met signaling in malignancy (Jeffers et al.,
1996). Recently, a direct genetic link between MET and human
cancer has been established by identifying activating mutations in
the Met kinase in hereditary and sporadic papillary kidney carci-
noma (Schmidt et al., 1997 and 1999).
 In situ hybridization has revealed that transcripts of the ligand
and the receptor are juxtaposed during embryogenesis, suggest-
ing a paracrine mode of interaction and a possible role for HGF/SF-
Met in epithelial-mesenchymal transitions occurring during devel-
opment (Sonnenberg et al., 1993 a and b). During organogenesis
hgf is expressed at the highest level in placenta, liver and limb
buds. The labyrinth layer of the placenta does not develop properly
in hgf or met null mice, which, as a consequence, die in mid-
gestation (Uehara et al., 1995; Schmidt et al., 1995). In these
embryos the liver starts developing normally, but, beginning at
E12.5, hepatocytes undergo massive apoptosis (Schmidt et al.,
1995). Finally, c-met null embryos lack limb and diaphragm mus-
cles (Bladt et al., 1995). This is due to the inability of mutant
myoblast precursors to de-laminate from the lateral lip of the
dermomyotome and initiate long-range migration in response to
HGF/SF (Bladt et al., 1995; Dietrich et al., 1999). This phenotype
recapitulates the ‘scatter’ effect originally seen in epithelial cells in
vitro.
Given the embryonal lethality of the homozygous null for hgf/sf
and met and considering that expression of the ligand and the
receptor persists postnatally and in the adult, there are a number
646       C. Ponzetto et al.
of questions left open on their physiological role. It remains to be
determined, for instance, whether HGF/SF-Met are involved in
morphogenesis of the mammary gland (as organ culture experi-
ments seem to indicate, Yang et al., 1995), or in liver and kidney
regeneration, as suggested by a number of in vivo experiments.
Lastly, nothing is known of the possible role for HGF/SF-Met in the
adult brain, where they are co-expressed in the cortex, hippocam-
pus and amygdala (Honda et al., 1995).
 Answers to some of these questions may come from tissue-
specific or conditional knockouts for the Met receptor. As an alterna-
tive approach, we have generated mice carrying met alleles of
different severity, taking advantage of the mechanism of signal
transduction used by the Met receptor. Met is linked to all its effectors
via ligand-induced phosphorylation of two critical tyrosine residues
located in a multifunctional docking site (Y1349VHVNATY1356VNV) in
the carboxy-terminal tail of the molecule (Ponzetto et al., 1994).
Effectors such as phosphatidylinositol 3-kinase (PI 3-Kinase), phos-
pholipase Cγ (PLCγ) and Src can be directly recruited to the receptor
via interaction with either of the two phosphotyrosines (Ponzetto et
al., 1993 and 1994). Grb2, the adapter for the Ras guanyl-nucleotide
exchanger Sos, binds at high affinity only to the YVNV motif, given its
requirement for an Asn in +2 (Songyang et al., 1993). Downstream
effectors can also be recruited indirectly via  the Gab-1 adaptor,
which is the major substrate for the Met kinase (Weidner et al., 1996).
Although in the yeast two hybrid system Gab-1 interacts directly with
the bidentate docking site (Weidner et al., 1996), in vivo it associates
with Met mainly via Grb2 (Fixman et al., 1997; Bardelli et al., 1997).
Thus the YVNV consensus is particularly critical for Met signaling,
since it links the receptor with the Ras pathway and with the Gab-1
adaptor. Gab-1 is essential in at least some of the cellular responses
to HGF (Fixman et al., 1997; Bardelli et al., 1997). It is, however, also
phosphorylated in response to other growth factors and cytokines,
among which are insulin and epidermal growth factor (EGF) (Holgado-
Madruga et al., 1996), nerve growth factor (NGF) (Holgado-Madruga
et al., 1997), and interleukin-6 (IL-6) (Takahashi-Tezuka, 1998).
Indeed, the phenotype of Gab-1 null embryos has features which
partially overlap with those observed not only in embryos lacking
HGF/SF, but also platelet growth factor (PDGF), EGF and leukemia
inhibiting factor (LIF), confirming that this molecule is a signal
amplifier common to a broad range of receptors (Itoh et al., 2000).
We and others have shown that Y→F mutation of the two
tyrosines of the multifunctional docking site (MetDouble, thereafter
indicated as MetD) abrogates receptor function in transfected cells
(Ponzetto et al., 1994; Zhu et al., 1994; Weidner et al., 1995;
Fixman et al., 1995). Conversely, N→H mutation in the YVNV
consensus (resulting in the loss of the Grb2 binding site, MetGrb2)
interferes with some (but not all) Met-mediated events. The signal
conveyed by the MetGrb2 mutant is in fact permissive for motility
(Ponzetto et al., 1996), but inadequate to promote branching
tubulogenesis in MDCK cells (Fournier et al., 1996), or for Tpr-Met-
mediated transformation (Ponzetto et al., 1996).
Having analysed the consequences of lowering Met signaling,
we next attempted to correlate Met-mediated biological effects with
the activation of specific pathways. This is more difficult for Met,
which relies on a bidentate docking site of mixed specificity, than
for other receptors (such as the PDGFR) possessing multiple
docking sites of high specificity. These in fact can be mutated one
by one to evaluate the consequences of the loss of single pathways
(Fantl et al., 1992). In the case of Met we modified the consensus
sequences of the multifunctional docking site to enhance direct
coupling with Grb2 (Met2xGrb2) or with PI 3-kinase (Met2xPI3K). Both
mutants resulted in a partial loss of biological function when tested
in transfected cells (Giordano et al., 1997; Bardelli et al., 1999),
confirming that the full spectrum of physiological effects of HGF
requires activation of a delicate balance of downstream effectors.
The Met signaling mutants described above have all been
transferred in the mouse by homologous recombination. This
review summarises the results obtained with the first set of muta-
tions, aimed at lowering Met signaling either severely (MetD) or
weakly (MetGrb2) (Maina et al., 1996; see Fig. 1). The mice
generated by introduction of the Met2xGrb and Met2xPI3K mutations
will be described elsewhere (Maina et al., submitted).
Results
Uncoupling effectors from the Met receptor in vivo results in
a mid-gestation lethal phenotype, similar to that of the met null
We sought to determine the importance of the bidentate docking
site Y1349VHVNATY1356VNV in Met signaling in vivo by introducing
Y→F mutations of tyrosine 1349 and 1356 in the mouse genome.
This was done by knocking-in the met locus a mutated human
cDNA fragment coding for the transmembrane and cytoplasmic
domain of the receptor (Maina et al., 1996). The resulting
recombinant Met protein (metD) consisted of a murine extracellular
domain fused to a human transmembrane and cytoplasmic domain
(Fig. 1). As a control we also knocked-in a wild type human MET
cDNA (metWT). Homozygous metWT/WT mice were normal, while
homozygous metD/D embryos died in utero in mid-gestation, with
the same timing and phenotype as the met  knockout (Maina et al.,
1996; Birchmeier and Gherardi, 1998). In particular, from E 12.5
on, in metD/D embryos the development of the placenta was
impaired and the size of the liver was reduced. Tunel staining
revealed numerous apoptotic nuclei in mutant hepatocytes. Fur-
thermore, these embryos lacked a subset of skeletal muscles
Fig. 1. Met signaling mutants expressed by knock-in mice. The
recombinant Met receptor is a chimeric protein consisting of a murine
extracellular domain (red) fused to a human transmembrane and cytoplas-
mic domain (black). metWt/Wt, chimeric protein with wild-tipe multifunctional
docking site; metD/D, chimeric protein without docking site; metGrb2/Grb2,
chimeric protein with disrupted Grb2 binding site.
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(hypaxial muscles of the limbs, diaphragm
and tip of the tongue) which all derive from
migratory precursors (Dietrich et al. 1999).
Deep muscles of the back and intercostals
(epaxial), which develop in situ (Denetclaw et
al., 1997), were normal.
The description of the skeletal muscle
defects of the metD/D embryos was further
refined by crossing these mice with
transgenics expressing the lacZ gene under
the myosin light chain promoter (Kelly et al.,
1997). Staining for β-galactosidase activity
revealed that, in addition to the absence of
appendicular muscles, metD/D embryos also
lacked superficial body wall muscles (Prunotto
et al., in preparation). The latter derive, like
appendicular muscles, from myoblast pre-
cursors found in the ventro-lateral lip of the
dermomyotome. However, in the flank these
precursors do not disperse, but remain
epithelially arranged while the dermomyotome
elongates as a continuous sheet of cells
(Dietrich et al., 1998); proliferation, rather
than active migration, appears to be the driv-
ing force of dermomyotomal elongation. This
defect suggests that during hypaxial muscle
development HGF/SF-Met may have a more
complex role than simply controlling emigra-
tion of myoblast precursors.
Finally, metD/D mutants were useful to
better define the emerging neurogenic role
for HGF/SF and Met (Maina and Klein, 1999).
In vitro studies suggested that HGF/SF could
act as a chemoattractant and a survival factor
for a subpopulation of embryonic motor neu-
tion in the YVNV consensus of the bidentate docking site, resulting
in the loss of Grb2 binding (metGrb2, Maina et al., 1996). This mutant
in transfected cells was permissive for motility but not for
tubulogenesis or transformation (Ponzetto et al., 1996; Fournier et
al., 1996). Homozygous metGrb2/Grb2 mice were born alive. The
placenta appeared to be morphologically normal, indicating that
the signaling output of the metGrb2 mutant is sufficient to rescue
placental development. The liver and motor and sensory innerva-
tion also appeared normal in metGrb2/Grb2 mice (Table 1; Maina et
al., 1996 and 1997).
On the other hand, metGrb2/Grb2 mice had hyperflexed forelimbs,
weak hind limbs, and showed respiratory distress, due to a signifi-
cant reduction of appendicular and diaphragm muscles (panel A
and B of Fig. 2 and Maina et al., 1996). Forelimbs seemed to be
more severely affected than hind limbs. In forelimbs, extensors
(derived from precursors of the dorsal pre-muscle mass) were
more severely reduced than flexors (Maina et al., 1996), thus
explaining the hyperflexed forelimb phenotype. Panel C and D of
Fig. 2 show sections of the hind limb of a control mouse and of a
metGrb2/Grb2 mutant. In this case, flexor muscles (including the
gastrocnemius), derived from the ventral pre-muscle mass, seemed
to be the most affected. It should be noted that in these mice
migratory precursors of appendicular muscles appeared to
delaminate properly from the somite, and that at least the initial
rons (Ebens et al., 1996; Yamamoto et al., 1997; Wong et al.,
1997). The analysis of metD/D embryos indeed showed defects at
the level of limb motor innervation (shortening of motor nerves and
reduction of branching, Maina et al., 1997). These studies also
revealed a role for HGF/SF-Met in survival and axonal outgrowth
of sensory (Maina et al., 1997) and sympathetic neurons (Maina et
al., 1998), and in differentiation of their precursors. The network of
sensory fibres innervating the skin of the limbs and the trunk was
found to be greatly reduced in metD/D embryos. Furthermore HGF/
SF dramatically enhanced NGF-induced neurite outgrowth from
cultured dorsal root ganglia (DRG) explanted from control mice,
while DRGs from metD/D mutants did not respond. Analysis of DRG
sections during the period of Met-dependent neurite outgrowth
(E12.5) revealed a consistent increase in cell death in the mutant
embryos (Maina et al., 1997). Lastly, cultures of superior cervical
ganglia from metD/D embryos were used to show that HGF en-
hances the survival and differentiation of sympathetic neuroblasts
and cooperates with NGF to enhance the axonal and neurite
outgrowth of sympathetic neurons (Maina et al., 1998).
Lowering the signaling threshold of the Met receptor in vivo
results in a hypomorphic mutant which develops to birth
To obtain a hypomorphic mutant for the Met receptor we
knocked-in the met gene a mutated cDNA carrying a N→H muta-
Fig. 2. Limb muscle defects of the metGrb2/Grb2 homozygous mutant. Homozygous mutant
neonates (B) display abnormal position of forelimbs compared with control littermates (A).
Histological analysis of sections distal to the knee of the hind limb from (C) control and (D) mutant
metGrb2/Grb2 neonates. Transverse paraffin sections were stained with haematoxylin and eosin. T,
tibia; F, fibula. Individual muscles are indicated by numbers: 1, extensor digitorum longus; 2, soleus;
3, gastrocnemius. (F) metGrb2/Grb2 survivor at age two weeks; the animal retains the hyperflexed
forelimb phenotype and is smaller than (E) the control.
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stages of their migration into the limb bud did not seem to be
compromised (Maina et al., 1996).
The majority of the metGrb2/Grb2 pups died in the first hours after
birth most likely because of their inability to breathe properly, due
to their weak diaphragm (Maina et al., 1996). Occasionally a few
metGrb2/Grb2 mutants survived into adulthood. During the first few
postnatal weeks they did not increase in size like the controls,
retained the hyperflexed phenotype in their forelimbs, and showed
a reduction in total muscle mass (see panel E and F of Fig. 2).
However with time these animals did recover in body size, muscle
mass and strength.
Surprisingly, histological analysis of muscle sections of
metGrb2/Grb2 new-borns also showed abnormal morphology in inter-
costal and deep back (epaxial) muscles. Epaxial muscles derive
from non-migratory precursors originating in the dorsal-medial lip
of the dermomyotome, a site which, like the ventro-lateral lip of the
somite, is positive for Met expression (Yang et al., 1996; Denetclaw
et al., 1997). Up to mid-gestation, however, Met signaling must be
redundant for the development of these muscles, since they are
unaffected in the more severe met null and metD/D embryos. The
appearance of this defect in later stages of myogenesis suggests
that Met may be required to mediate proliferation of fetal myoblasts
from which secondary fibres are formed. Indeed bromo-deoxyuridine
incorporation into myogenic nuclei at E17.5 was found to be
reduced in intercostal muscles of metGrb2/Grb2 embryos, suggesting
that HGF/SF may contribute to trigger proliferation of all fetal
myoblasts in vivo (Maina et al., 1996).
The temporal pattern of met expression in fetal limb muscles
supports this possibility. Met is highly expressed up to day E11.5 in
the proliferating embryonal myoblasts forming the dorsal and ventral
pre-muscle masses (see panels A and E in Fig. 3). At E12.5 met is
downregulated in the differentiated primary fibres in the limbs. Its
expression is maintained only distally along the digits, presumably in
correspondence of pre-cartilaginous condensations (panels B and F
in Fig. 3). At day 13.5, in concomitance with resumption of prolifera-
tion of fetal myoblasts, met is re-expressed in the developing muscles
(panel C and G in Fig. 3). Interestingly, at E14.5 the highest level of
met expression is in the region of the future joints, where expression
of HGF has also been demonstrated (Takebayashi et al., 1995). Thus
the HGF/SF-Met pair could play a role in chondrocyte development
as well.
HGF/SF enhances DNA synthesis in cultured epaxial fetal
myoblasts
To verify the effect of HGF/SF on epaxial fetal myoblasts, deep
back muscles were removed from E13.5 embryos, digested with
collagenase and cultured. Addition of HGF to these cultures
resulted in a 24% increase in BrdU incorporation in myogenic
(desmin positive) cells relative to controls (Fig. 4). A similar
proliferative response was elicited by basic fibroblast growth factor
(bFGF). This in vitro result supports a possible role for HGF/SF on
fetal myoblast proliferation in vivo.
HGF/SF promotes proliferation and delays differentiation of
satellite cells in culture
A proliferative role for HGF/SF has been demonstrated for
satellite cells, myoblasts which lie quiescent under the basal
lamina of adult muscle fibres. Met is expressed in quiescent
satellite cells (Cornelison and Wold, 1997), and HGF/SF is capable
of activating satellite cells in vitro (Allen et al., 1995; Gal-Levi et al.,
1997; Tatsumi et al., 1998). This has suggested a potential role for
HGF/SF in the early phase of muscle regeneration, when satellite
cells must re-enter the cell cycle. Indeed, in the rat, transcription of
HGF/SF increases during the first few days after muscle injury
(Jennische et al., 1993). To verify the proliferative effect of HGF/SF
on satellite cells, we prepared cultures from single muscle fibre
explants obtained from adult mice (panel A of Fig. 5; Bischoff,
1986). Such preparations result in a higher yield and purity of
satellite cells than those obtained starting from minced muscle.
Single fibres were maintained in enriched growth medium until the
Fig. 3. Expression of met during limb
development. Whole-mount in situ hy-
bridization with a digoxigenin labelled
met probe. A-D, fore limb; E-H, hind
limb. (A and E) At E11.5, met is highly
expressed in proliferating embryonal
myoblasts. (B and F) At E12.5, met
expression is downregulated proximally
and persists distally along the digits,
corresponding to pre-cartilaginous con-
densations. (C and G) At E13.5, met is
re-expressed in the developing mus-
cles, in concomitance with the prolifera-
tion of fetal myoblasts. (D and H) At
E14.5, met expression is mainly local-
ised in the joints region.
TABLE 1.
PHENOTYPE OF EMBRYOS HOMOZYGOUS FOR THE INDICATED
MET SIGNALING MUTANTS
Placenta Liver Muscle Motor Sensory
(Limb and Nerves nerves
body wall)
met Wt/Wt + + + + +
met D/D - - - - -
met Grb2/Grb2 + + + + +
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few associated satellite cells migrated out of the basal lamina
(panel B Fig. 5). On the third day, cultures were switched to
differentiation medium with or without addition of recombinant
HGF/SF. Fig. 5 shows the appearance of these cultures five days
after the switch. Satellite cells rapidly differentiated into small
myotubes in differentiation medium (panel C). Addition of HGF
resulted in a delay in differentiation and a significant increase of
small round mono-nucleate satellite cells (panel D). A similar dual
effect of HGF/SF has also been observed in cultures of chicken
satellite cells (Gal-Levi et al., 1997; Miller et al., 2000).
 HGF/SF induces cyclin D1 expression and nuclear transloca-
tion of cdk4 in C2C12 myogenic cells
To understand the basis for the proliferative response of myoblasts
to HGF/SF we studied its effects on cyclin D1 and cdk4, which are
involved in the control of cell cycle progression and in inhibition of
myogenic differentiation. For these studies we used the C2C12
myoblast cell line, where it has been shown that myogenic differen-
tiation and MyoD expression can be inhibited by transfection of a
constitutively active Met kinase (Anastasi et al., 1997).
Panel A in Fig. 6 shows that cyclin D1 is undetectable in the nuclei
of starved C2C12 cells. A six hours treatment with HGF/SF induced
the appearance of cyclin D1 in the majority of the myogenic nuclei
(panel B). Concomitant with this increase there was also nuclear
translocation of cdk4 (panels C and D). Modulation of cyclin D1 levels
and nuclear translocation of the cyclin D1-cdk4 complex has been
described as a major mechanism by which mitogens inhibit myo-
genic differentiation (Zhang et al., 1999 a and b).
Discussion
The approach that we have taken to modify Met function in vivo
(interfering with Met signaling by mutation of SH2 docking sites)
was based on knowledge of the mechanism adopted by this and
other tyrosine kinase receptors to carry out signal transduction.
Tyrosine kinase receptors recruit cytoplasmic effectors via short
recognition motifs, composed of phosphotyrosine followed by
three to five downstream residues, which are generated by
autophosphorylation upon ligand-dependent receptor activation.
Effectors associate with the receptor with their own SH2 domains
or by forming a complex with SH2-containing adaptors.
Phosphotyrosine-SH2 interactions are usually quite specific, thus
the sequence of the SH2 docking sites on a given receptor dictates
which SH2-containing targets will associate with the receptor (for
a review see Pawson and Scott, 1997).
Met, the receptor for HGF/SF and the closely related members
of its family Ron and Sea, represent an unusual case. Rather than
possessing numerous specific docking sites, they rely on two
closely spaced phosphotyrosines in their carboxy-terminal tail to
convey the bulk of their signaling activity (Ponzetto et al., 1994;
Iwama et al., 1996; Park and Hayman, 1999). These tyrosine
residues are part of a bidentate ‘multifunctional’ docking site
(Y1349VHVNATY1356VNV in Met), which can bind a number of SH2-
containing signaling proteins. In all three members of the Met
family the second phosphotyrosine is embedded in an optimal
motif for the Grb2 adaptor. Grb2 links the Met receptor with two
critical effectors, the Ras guanyl-nucleotide exchanger Sos and
the Gab-1 protein (Ponzetto et al., 1994; Fixman et al., 1997;
Bardelli et al., 1997). Gab-1 is a signal amplifier common to other
tyrosine kinase receptors (Holgado-Madruga et al., 1996). It con-
tains a pleckstrin domain and a number of potential phosphoryla-
then fixed and stained using anti-desmin (Cy-3, red) and anti-BrdU (FITC, green) antibodies to discriminate proliferating myogenic from non-myogenic cells. (A) BrdU
incorporation in low serum condition shows few BrdU/desmin positive cells. (B) Addition of 50 U/ml of recombinant HGF/SF to low serum medium resulted in a
24 % increase in the number of double-labelled cells relative to (A). (C) A similar proliferative response was elicited using 20 ng/ml of recombinant bFGF.
Fig. 5. HGF/SF promotes proliferation and delays differentiation of
satellite cells in culture. High purity satellite cell cultures were obtained
using single muscle fibre explants from adult mice. (A) Isolated single
muscle fibres were maintained in enriched growth medium until (B) the
few associated satellite cells (black arrows) migrated out of the basal
lamina (two to three days). Cultures were then switched to low serum and
photographed five days later. (C) Lowering the serum concentration
resulted in rapid differentiation of satellite cells into small myotubes. (D)
The addition of 50 U/ml of recombinant HGF/SF resulted in fewer myotubes
and in an increase of small round mononucleate satellite cells.
Fig. 4. HGF/SF stimulates BrdU incorpora-
tion in epaxial fetal myoblasts in culture.
Deep back muscle was taken from E13.5 em-
bryos of mixed genetic background, digested
with collagenase, and plated for 5 h in high
serum medium, after a 10 min pre-plating to
remove part of the fibroblasts. The medium was
then switched to low serum with or without
growth factor for 8 h before the addition of BrdU.
Cells were incubated with BrdU overnight and
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tion sites, some of which are optimal binding sites for PI 3-kinase,
PLC-γ, and the tyrosine phosphatase SHP2. Gab-1 is critical for
mediating HGF-induced branching tubulogenesis in MDCK cells
(Weidner et al., 1996; Maroun et al., 1999).
We tested in vivo the effects of abrogating recruitment of SH2-
containing effectors to the Met receptor without interfering with its
tyrosine kinase activity, by converting to phenylalanine the two
tyrosine residues of the Met multifunctional docking site (MetD) via
homologous recombination. The resulting phenotype showed the
same defects as the met null (placenta, liver, muscle, and motor
innervation), confirming for the first time in mice the importance of
phosphotyrosine-SH2 interactions in tyrosine kinase receptor
signaling (Ponzetto, 1998).
 In particular, from E13.5 on, the placenta of metD/D embryos
was paler and smaller than controls. Analysis of the placenta in hgf
and met null mice revealed a reduction in the trophoblast cells of
the labyrinth layer (Schmidt et al., 1995; Uehara et al., 1995).
Interestingly, the same defect has recently been described in Gab-
1 null mice (Itoh et al., 2000), suggesting that HGF/SF-Met signaling
through Gab-1 is critical for development of these cells. metD/D
mutants also have an apoptotic liver and lack muscles of the limbs,
diaphragm and tip of the tongue, as observed in the met null (Bladt
et al., 1995). In these embryos, muscle precursors at limb level in
the lateral dermomyotomal lips do not undergo de-epithelialization
and do not enter the limb bud, confirming that Met signaling in
myogenic precursors is essential for the initial steps of long-range
migration.
Interestingly, however, the Met ligand is expressed along the
entire route followed by migratory cells and in their target sites,
suggesting that HGF/SF may guide muscle precursors toward their
final destination (Dietrich et al., 1999). Experiments done by
applying beads soaked with HGF/SF to the flank of chick embryos
to verify its chemotactic effect were inconclusive (Heymann et al.,
1996; Brand-Saberi et al., 1996).  The strongest indication of a true
chemotactic role for HGF/SF comes from the phenotype of
transgenics expressing HGF/SF ectopically. In these mice there is
aberrant development of muscles around the spinal cord, implying
misrouting of migratory myoblasts toward the ectopic source of
HGF/SF (Takayama et al., 1996). However, HGF/SF in these
animals is probably at far higher than physiological levels. The
prolonged requirement for active Met signaling during long range
migration may fulfil additional requirements of migrating cells, such
as the need to maintain the undifferentiated state (Scaal et al.,
1999) or to sustain their proliferation.
The additional Met mutant that we tested in vivo was obtained
by modifying the consensus sequence of the second of the two
tyrosines of the multifunctional docking site to uncouple the Grb2
adaptor (Y1356VNV→Y1356VHV, MetGrb2). This mutation, besides
impairing activation of the Ras pathway (Besser et al., 1997) has
the effect of lowering overall Met signaling, since Grb2 is respon-
sible for linking the Met receptor not only to Sos but also to the
signal amplifier Gab-1. In transfected MDCK cells, over-expres-
sion of Gab-1 can rescue the branching tubulogenesis defect of
this mutant, but not of the MetD mutant. The MetGrb2 mutant may
thus retain some residual binding capacity for Gab-1, since the
latter may directly interact with the mutated bidentate docking site
(Maroun et al., 1999).
The phenotype of the metGrb2/Grb2 mutants was milder than that
of the metD/D mice. The residual signaling ability of MetGrb2 seems
to be sufficient for normal development of placenta, liver, and motor
and sensory innervation. The tissue most sensitive to the lowered
Met signaling threshold appeared to be skeletal muscle.
metGrb2/Grb2 mice showed severe reduction of appendicular and
diaphragm muscles, deriving from migratory precursors. Muscle
cell progenitors, however, did not seem to be impaired in their
ability to delaminate from the somite and to start their migration.
Similarly, the timing of their differentiation did not seem to be
altered. A possible explanation for the partial defect observed
could be failure of myogenic precursors to survive or to proliferate
properly, while on route toward their site of destination. This would
again imply a more complex role for HGF/SF-Met on embryonal
myoblasts than that of mediator of somite de-epithelialization and
chemotaxis.
There are several other hints that support this hypothesis. First
of all by crossing the metD mutant with mice expressing lacZ under
the myosin light chain promoter (Kelly et al., 1997) we observed
that metD/D embryos also lack superficial body wall muscles,
besides muscles of the limbs. The former belong to the hypaxial
group deriving from the ventro-lateral dermomyotome, but their
precursors do not undergo active migration. These muscles are
laid down along the flanks of the embryo as the lateral lips of the
Fig. 6. HGF/SF induces cyclin D1 expression and cdk4 nuclear trans-
location in C2C12 myogenic cells. C2C12 myoblasts were starved at low
serum for 14 h and stained using antibodies specific for (A,B) cyclin D1 and
(C,D) cdk4. (A) Cyclin D1 is undetectable in the nuclei, stained in Red by
DAPI. (B) A 6 h treatment with 50U/ml of recombinant HGF/SF induced
cyclin D1 expression (FITC, green). (C, D) The same treatment of C2C12
myogenic cells resulted in the nuclear translocation of cdk4 (Cy-3 red). (E,F)
DAPI staining.
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dermomyotome elongate by continuous proliferation. Thus the role
of Met in their development must be distinct from that of mediating
somite delamination and/or long range migration.
Furthermore, met is expressed from early embryonic stages in
the dorsal lip of the dermomyotome where precursors of epaxial
muscles originate (Yang et al., 1996). In metD/D and in metGrb2/Grb2
mutants epaxial muscles are normal up to mid-gestation, indicating
that Met signaling is redundant during primary myogenesis. How-
ever, histological analysis of these muscles in metGrb2/Grb2 mice at
birth reveals a reduction in secondary fibres. Met may thus contrib-
ute to the development of these muscles at the onset of secondary
myogenesis, when fetal myoblasts re-enter the cell cycle and
resume proliferation, after temporary quiescence. Indeed the pro-
liferative capacity of fetal myogenic cells appears to be reduced in
metGrb2/Grb2 embryos, as indicated by lower BrdU incorporation in
vivo. In support of this hypothesis, we have now shown that
cultures of epaxial myoblasts obtained from E13.5 embryos re-
spond to HGF/SF by an increase in BrdU incorporation. Neverthe-
less, the role of HGF/SF in fetal myoblast proliferation remains
controversial. In fact Dietrich et al. (1999), who recently obtained
perinatal met  null fetuses after tetraploid rescue of the placenta,
did not find any defect in trunk muscles.
On the other hand several reports describe a proliferative effect
of HGF/SF on satellite cells (Allen et al., 1995; Gal-Levi et al., 1997;
Tatsumi et al., 1998 and this review). This, together with the
observed increased level of expression of HGF/SF in the first few
days after muscle injury (Jennische et al., 1993) has suggested
that HGF/SF may trigger muscle regeneration in vivo. Proof of
involvement of HGF/SF-Met in regeneration (of muscle or of any
tissue) awaits a viable loss-of-function model. This will most likely
be a conditional knockout.
We have recently obtained a viable metGrb2/Grb2 mutant making
use of a modified knock-in targeting vector in which the neo
cassette (see Maina et al., 1996) was flanked by loxP sites. Neo
sequences are known to de-stabilise transcripts, and for this
reason it is desirable to remove them from recombinant loci. This
was done by crossing the new mutant with the Cre Deleter
(Schwenk et al., 1995). The resulting metGrb2/Grb2neo- mutants are
viable and apparently normal. This suggests that the previous
metGrb2/Grb2 mice represent a ‘sensitised’ model, where the effects
of the partial loss of function mutation (Y1356VNV→Y1356VHV) and
of a decreased level of met transcript (and protein) add up to
produce the observed phenotype. Viable metGrb2/Grb2neo- mutants,
although apparently free of developmental defects, may still prove
useful to evaluate the role of HGF/SF-Met in tissue and organ
regeneration, and their function in adult tissues such as brain,
where a higher threshold of Met signaling may be required.
Since our first report on the generation of mice expressing Met
signaling mutants by homologous recombination (Maina et al.,
1996), the same approach has been applied to a number of
receptors. Y→F mutation of the tyrosine residue leading to activa-
tion of PLCγ in the Fibroblast Growth Factor Receptor 1 (FGFR1)
surprisingly revealed that this docking site mediates a negative
rather than a positive signal (Partanen et al., 1998). On the other
hand, mutation of the Shc binding site in trkB unveiled a difference
in the signaling output triggered by the two neurotrophins NT4 and
BDNF, with the former being less potent than the latter in eliciting
the MAP kinase response (Minichiello et al., 1998). Mutation of the
two PI 3-kinase docking sites in the PDGF-β receptor did not
interfere with development, but cells derived from the mutants were
less chemotactic and lost the ability to contract collagen gels in
response to PDGF (Heuchel et al., 1999). Furthermore, injection of
a mast cell de-granulating agent in these mice led to a decrease in
interstitial fluid pressure, resulting in edema. Thus the signaling
mutant revealed a PI 3-kinase-mediated role for the PDGF-β
receptor in interstitial fluid homeostasis. Loss of the PI 3-kinase
docking site in the Kit receptor induced a gender and tissue-
specific defect (Blume-Jensen et al., 2000). Although there were
no hematopoietic or pigmentation defects in homozygous mutant
mice, males were sterile, due to a block in spermatogenesis.
Lastly, knock-in mice expressing signaling mutants of gp130 (a
common subunit for the interleukin-6 family of cytokine receptors)
were born apparently normal but with immunological defects in the
case of SHP2 signal-deficient mice, and were perinatal lethal (as
the gp130 null) in the case of the STAT3 signal-deficient mice
(Ohtani et al., 2000).
In conclusion, signaling mutants represent a valuable tool to
generate a spectrum of alleles which may help to unravel physi-
ological roles for the corresponding receptors during development
and in the adult, and may allow dissection of pathways involved in
the biological response to the ligand.
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